Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections

NCT00156377 | Completed Phase 4

• 1 other identifier: 4710F-186
• Study Type: interventional
• Target: 1,200
• Locations: 1 country
• Sites: 1

Brief Summary

In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections.

Conditions

Cross Infection; Staphylococcal Infections

Keywords

Mupirocin; Staphylococcus aureus; Nasal Cavity; Preventive measures

Outcome Measures

Primary Outcomes (1)

• Staphylococcus aureus infection any time after 5 days of mupirocin ointment

Secondary Outcomes (1)

• Presence or abscence of risk factors associated with S. aureus infections at any time during the hospital stay

Interventions

Mupirocin DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients admitted to selected units in clinics for anaesthesiology, hemato-oncology, cardiac surgery, and orthopedics at the University Hospital of Muenster (following information on the study and agreement of the patient).

You may not qualify if:

• Patients infected with S. aureus at admission
• S. aureus infection within 48 hours following admission
• Patients detected to be carrier of Methicillin-resistant S. aureus
• Hospital stay shorter than 72 hours
• Patients with anatomic abnormalities in the anterior nares
• Allergy or hypersensitivity to mupirocin or other substances of the nasal ointment
• Persons younger than 18 years
• Known pregnancy
• Persons with psychiatric diseases
• Persons with limited contractual capability and judiciousness

Sponsors & Collaborators

• University Hospital Muenster: lead
• GlaxoSmithKline: collaborator

Study Sites (1)

Institute of Medical Microbiology, University Hospital of Muenster

Münster, 48149, Germany

Location

Related Publications (2)

• von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001 Jan 4;344(1):11-6. doi: 10.1056/NEJM200101043440102.

  PMID: 11136954 BACKGROUND

• von Eiff C, Kipp F, Becker K. Intranasal mupirocin to prevent postoperative infections. N Engl J Med. 2002 Oct 10;347(15):1207-8; author reply 1207-8. doi: 10.1056/NEJM200210103471518. No abstract available.

  PMID: 12374887 BACKGROUND

Related Links

• Home page of the Institute of Medical Microbiology of the University Hospital of Muenster

MeSH Terms

Conditions

Cross Infection; Staphylococcal Infections

Interventions

Mupirocin

Condition Hierarchy (Ancestors)

Infections; Iatrogenic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses

Intervention Hierarchy (Ancestors)

Epoxy Compounds; Ethers, Cyclic; Ethers; Organic Chemicals; Pyrans; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fatty Acids; Lipids

Study Officials

• Christof von Eiff, MD

  University Hospital of Muenster, Institute of Medical Microbiology

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 8, 2005
• First Posted: September 12, 2005
• Study Start: November 1, 2002
• Last Updated: May 25, 2010

Record last verified: 2005-09

Locations

DE (1)